Studies have indicated that deletion or dysfunction of IRF-1 can induce tumor occurrence or progression in various cancers, including gastric cancer [17], breast cancer [30] and hepatocellular carcinoma [31]. Here, IRF1 is linked to hepatocellular carcinoma.